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Summary 
We examined the simultaneous uptake of porphyrin and 
low-density lipoprotein (LDL) by 4 established cell lines of glioma and 
normal fibroblasts using flow cytometry (FCM).  The results indicated 
porphyrin and LDL showed competitive conjugation with the LDL receptor.  
These results support the theory of the porphyrin uptake via the LDL 
receptor.  
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Introduction 
 Porphyrin is selectively uptaken by tumor cells [1,2].  Because of 
this property, porphyrin has been used as a tumor-targeting agent in 
photodynamic therapy [1,2].  Some researches using porphyrin as boron 
carrier for boron neutron capture therapy (BNCT) are in progress [3-8].   
Porphyrin is believed to be uptaken via the low-density lipoprotein (LDL) 
receptor [2,9,10], however the mechanism of uptake of porphyrin is not 
completely understood.  Tumor cells, neoplastic astrocytes in particular 
highly express the LDL receptor [11].  We examined simultaneous 
porphyrin and LDL uptake into 4 established cell lines of glioma and 
normal fibroblast using flow cytometry (FCM) and analyzed the mode of 
conjugation of porphyrin and LDL with the LDL receptor.  
 
Materials and Method 
Cell preparation 
  A-172, U-251, 9L, ONS, NB-1 cell lines were cultured for several 
days in RPMI 1640 medium (Gibco, New York, NY, USA) or Earle’s 
minimum essential medium (MEM) solution (Gibco).  A-172 and U-251 
are human glioblastoma cell lines.  9L is a rat gliosarcoma cell line.  
ONS is a human medulloblastoma cell line.  NB-1 is a rat fibroblast cell 
line.  They were maintained at 37o   C in an atmosphere of 5% CO2 in 
air.  Cells were grown in petri dishes and detached with 0.25% trypsin 
solution. The cells were washed with phosphate buffered saline (PBS).  
Each cell suspension was centrifuged and pellets of about 1x106 cells were 
resuspended in RPMI 1640 medium or Earle’s MEM solution and cultured 
with fluorescent-labeled LDL or fluorescent porphyrin.  In the case of 
LDL staining, the cells were stained with fluorescent labeled LDL, that is, 
acetylated LDL labeled with 
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine perchlorate 
(Dil-Ac-LDL, Biomedical Technologies, Stoughton, MA, USA) at the 
concentration of 25μg/ml in RPMI 1640 for 2 hours at 37˚C in an 
atmosphere of 5% CO2 in air. In that of porphyrin staining, the cells were 
stained with ATX-S10・Na, (Photochemical Co., LTD., Okayama, Japan) at 
the concentration of 25μg/ml in RPMI 1640 for 2 hours at 37˚C in an 
atmosphere of 5% CO2 in air.  The chemical name of ATX-S10・Na is 
13,17-bis (1-carboxypropionyl) 
carbamoylethyl-8-ethenyl-2-hydroxy-3-hydroxy iminoethylidene-2, 7,12, 
18- tetramethyl-porphyrin sodium salt; its molecular formula is 
C42H41N7O12Na4, and its molecular weight is 927.79 [4]. 
LDL receptor stability against trypsin 
 We investigated whether LDL receptors are changed with trypsin 
solution.  One group of cells was detached with 0.25% trypsin solution.  
Another group of cells was mechanically detached without trypsin solution.  
Each cell were washed with PBS and centrifuged.  Each pellets were 
resuspended in RPMI 1640 medium and cultured with Dil-Ac-LDL at the 
concentration of 25g/ml in RPMI 1640 for 2 hours at 37˚C in an 
atmosphere of 5% CO2 in air.  Each cell suspension was centrifuged and 
the pellets were fixed with ice-cooled 70% ethanol over night. 
  Staining with LDL and porphyrin 
  Cells were stained according to different protocols as follows.  
Cells in Group 1(sequential LDL-porphyrin) were first stained with 
Dil-Ac-LDL at the concentration of 25μg/ml in RPMI 1640 for 2 hours at 
37˚C in an atmosphere of 5% CO2 in air and subsequently stained with 
ATX-S10-Na at the concentration of 25μg/ml in RPMI 1640 for 2 hours at 
37˚C in an atmosphere of 5% CO2 in air.  Cells in Group 2(sequential 
porphyrin-LDL) were first stained with ATX-S10-Na at the concentration 
of 25μg/ml in RPMI 1640 for 2 hours at 37˚C in an atmosphere of 5% CO2 
in air and then stained with Dil-Ac-LDL at the concentration of 25μg/ml in 
RPMI 1640 for 2 hours at 37˚C in an atmosphere of 5% CO2 in air.  
Cells in Group 3(simultaneous) were simultaneously stained with 
Dil-Ac-LDL and ATX-S in RPMI 1640 for 2 hours at 37˚C in an 
atmosphere of 5% CO2 in air.  The concentration of Dil-Ac-LDL was 
25μg/ml and that of ATX-S10 was gradually increased from 0.5 to 50 
μg/ml.  Each cell suspension was centrifuged and the pellets were fixed 
with ice-cooled 70% ethanol over night and then stored at 4˚C. 
Inhibition of LDL receptor with monoclonal antibody 
 Cells were incubated with anti-human LDL receptor mouse 
monoclonal antibody (Progen biotechnik GmbH, Heidelberg, Germany) at 
the concentration of 5 ug/ml in RPMI 1640 for 1 hour at 37˚C in an 
atmosphere of 5% CO2 in air.  Each cell were washed with PBS and 
centrifuged.  Each pellets were resuspended in RPMI 1640 medium and 
cultured with Dil-Ac-LDL or ATX-S10 at the concentration of 25g/ml in 
RPMI 1640 for 2 hours at 37˚C in an atmosphere of 5% CO2 in air.  Each 
cell suspension was centrifuged and the pellets were fixed with ice-cooled 
70% ethanol over night and then stored at 4˚C. 
Analysis of the cells by flow cytometry  
 Cell suspensions were filtered through a mesh with 2mm pores 
(Becton Dickinson, San Jose, CA, USA) to remove debris or clusters of 
cells.  The 1x105 cells of each cell line were analyzed by flow cytometry. 
The flow cytometric data acquisition was conducted using FACSCalibur 
(Becton Dickinson).  The peak-activated wavelength of Dil-Ac-LDL is 
420nm and its peak fluorescent wavelength is 560nm.  The activated 
wavelength of ATX-S10 is 400-417nm and its peak fluorescent wavelength 
is 677nm[4,9].  DNA content stained with Dil-Ac-LDL was measured 
within the FL2 range.  The fluorescence of ATX-S10 was measured 
within the FL3 range.  Data were analyzed with Cell Quest software 
(Becton Dickinson).   
 
Results 
LDL receptor stability against trypsin 
 Figure 1 show the histogram of FL2 of A-172 (upper) and U-251 
(lower) cells.  The results of the cells detached using trypsin solution are 
left side and the results of the cells mechanically detached are right side. 
The peaks of FL-2 histogram were almost same.  The histogram using 
trypsin solution, however, shows sharper peak.  And cells were 
completely detached by using trypsin solution.  So we used trypsin 
solution to detach cells in following experiments. 
Staining with LDL and porphyrin 
Figures 2-6 show the dot plot of the relation between FL2 and FL3 
(upper), histogram of FL2-height (middle) and histogram of FL3-height 
(lower) of A-172 and 9L cell lines.  The vertical axis of the dot plot of the 
relation between FL2 and FL3 is FL3 fluorescence; the horizontal axis is 
FL2 fluorescence.  The horizontal axis of the histograms corresponds to 
FL2 or FL3 fluorescence and the vertical axis corresponds to cell number.  
The porphyrin and LDL uptakes by tumor and normal fibroblast cells 
showed almost no difference among cell lines.  Cells stained for LDL 
demonstrated fluorescence only in FL2 (Fig. 2).  Cells stained for 
porphyrin demonstrated fluorescence only in FL3 (Fig. 3).  Cells in  
group 1 (sequential LDL-porphyrin) showed fluorescence only in FL2 (Fig. 
4).  Cells in group 2 (sequential porphyrin-LDL) showed fluorescence 
only in FL3 (Fig. 5).  These results mean the first compound was uptaken 
by tumor cells whereas the secondary compound was not.  Cells in group 
3 (simultaneous) showed fluorescence in both FL2 and FL3.  Sequential 
changes in porphyrin concentration in the medium were associated with 
sequential changes in LDL fluorescence (Fig. 6).   
Inhibition of LDL receptor with monoclonal antibody 
 Figure 7 shows FL2 histogram of A-172 (upper) and U-251 (lower) 
cells incubated with Dil-Ac-LDL.  The results of cells treated with 
anti-LDL receptor monoclonal antibody are in right side and those without 
the treatment is in left side.  The peak fluorescence of A-172 and U-251 
with anti-LDL monoclonal antibody was almost same as those without 
anti-LDL monoclonal antibody.  The FL2 fluorescence was not 
suppressed by the anti-LDL monoclonal antibody 
 Figure 8 shows FL3 histogram of A-172 (upper) and U-251 (lower) 
cells incubated with ATX-S10.  The results of cells treated with anti-LDL 
receptor monoclonal antibody are in right side and those without the 
treatment is in left side.  The peak fluorescence of A-172 and U-251 with 
anti-LDL monoclonal antibody was almost same as those without anti-LDL 
monoclonal antibody.  The FL3 fluorescence was not suppressed by the 
anti-LDL monoclonal antibody. 
 
Discussion  
 Rapidly proliferating tumor cells show high cholesterol uptake via 
LDL receptor-mediated endocytosis and have been shown to exhibit 
enhanced LDL receptor activity and large amounts of LDL receptors on the 
surface of each cell [9,11,12-14].  As for the mechanism of porphyrin 
uptake, the low-density lipoprotein (LDL) receptor-mediated pathway was 
reported to be the carrier of porphyrin into the cells [9,10,12].   
The anti-LDL receptor monoclonal antibody could not block the 
uptake both of Dil-Ac-LDL and porphyrin.  This result means that both 
porphyrin (ATX-S10) and Dil-Ac-LDL have competitive receptor, which 
differ from the LDL receptor blocked by the present study. The antibody 
we used recognized one epitope of human LDL receptor. Further study 
should be performed to determine the exact receptor epitope of both 
porphyrin and Dil-Ac-LDL. Because this antibody did not block 
Dil-Ac-LDL uptake into the glioma cells, it is understandable that this 
antibody could not block the porphyrin uptake into the glioma cells.  If the 
monoclonal antibody completely blocked the LDL receptor, the uptake of 
porphyrin would be investigated more in detail. 
Our results demonstrated a competitive conjugation of porphyrin 
and LDL with the same LDL receptor on tumor cells.  Variability of LDL 
and porphyrin uptake by different types of tumor and normal cell lines was 
not recognized in our study.  These results indicate that the LDL receptor 
can be easily saturated with porphyrin or LDL in vitro studies.  Porphyrin 
uptake by tumor cells was influenced with the concentration of concomitant 
LDL.  So to improve porphyrin uptake by tumor cells, suppression of 
LDL concentration in target tumors or upregulation of the LDL receptor in 
the tumor cells may be effective as a therapeutic strategy.  Local control 
of LDL concentration in the tumor may be difficult in vivo.  We will 
investigate the possibility of modifying the LDL concentration in tumor 
tissue in future studies. 
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Legends for figures 
Fig. 1  A-172 (upper) and U-251 (lower) cells stained for LDL showed 
peak fluorescence in FL2.  The results of cells using trypsin solution (left) 
were almost same as the results of cells without trypsin (right). 
Fig. 2  A-172 cells stained for LDL demonstrated fluorescence only in 
FL2.  The upper figure is the dot plot of the relation between FL2 and FL3,  
the middle one is the histogram of FL2-height and the lower one is the 
histogram of FL3-height.   
Fig. 3  A-172 cells stained for porphyrin demonstrated fluorescence only 
in FL3.       
Fig. 4  A-172 cells stained for LDL (left) demonstrated fluorescence only 
in FL2, and these stained for porphyrin (middle) showed fluorescence only 
in FL3.  The cells in Group 1 (LDL-porphyrin, right) showed fluorescence 
only in FL2, almost same as those stained with porphyrin only. 
Fig. 5  9L cells stained for LDL (left) demonstrated fluorescence only in 
FL2, and these stained for porphyrin (middle) showed fluorescence only in 
FL3.  These cells in Group 2(porphyrin-LDL, right) showed fluorescence 
only in FL3, almost same as those stained with LDL only. 
Fig. 6  A-172 cells in Group 3 showed fluorescence in both FL2 and FL3.  
Continuous changes in porphyrin concentration in the medium were 
associated with continuous changes in LDL fluorescence.  The 
concentrations of LDL and porphyrin were described in the figure. 
Fig. 7  A-172 (upper) and U-251 (lower) cells stained for LDL showed 
peak fluorescence in FL2.  The results of cells with anti-LDL receptor 
monoclonal antibody (right) were almost same as the results of cells 
without the antibody (left). 
Fig. 8  A-172 (upper) and U-251 (lower) cells stained for porphyrin 
showed peak fluorescence in FL3.  The results of cells with anti-LDL 
receptor monoclonal antibody (right) were almost same as the results of 
cells without the antibody (left). 
